Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lorcaserin - Eisai Inc

X
Drug Profile

Lorcaserin - Eisai Inc

Alternative Names: APD-356; Belviq; Belviq XR; E2023; Lorcaserin controlled-release; Lorcaserin extended-release; Lorcaserin hydrochloride; Venespri

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arena Pharmaceuticals
  • Developer Arena Pharmaceuticals; CY Biotech; Eisai Inc; Ildong Pharmaceutical
  • Class Antiepileptic drugs; Benzazepines; Obesity therapies; Small molecules
  • Mechanism of Action Serotonin 2C receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dravet syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Obesity
  • Phase III Dravet syndrome
  • Clinical Phase Unknown Epilepsy
  • Discontinued Smoking withdrawal

Most Recent Events

  • 28 Nov 2022 Lorcaserin is still in the phase III MOMENTUM 1 trial for Dravet syndrome (In children) in USA, Canada (PO) (NCT04572243)
  • 11 Mar 2022 Arena Pharmaceuticals has been acquired and merged into Pfizer
  • 13 Nov 2021 Updated efficacy data from the phase III/IV CAMELLIA-TIMI 61 trial in Obesity presented at the American Heart Association Scientific Sessions 2021 (AHA-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top